Tislelizumab: An effective anti-PD-1 antibody for the treatment of advanced basal cell carcinoma of the prostate
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Prostate basal cell carcinoma (BCC) is rare and challenging to treat. This study shows tislelizumab effectively treats advanced prostate BCC, offering a new therapeutic option.
Area Of Science
- Oncology
- Urological Pathology
Background
- Basal cell carcinoma (BCC) of the prostate is a rare malignancy with unclear behavior.
- Existing literature indicates invasive potential and high malignancy, requiring careful management.
- Effective treatments for advanced prostate BCC, particularly using programmed cell death protein-1 (PD-1) inhibitors, are lacking.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...